Abstract 588P
Background
HER2 alterations in non-small cell lung cancer (NSCLC) are recognized as challenging therapeutic targets with unmet clinical needs. While the recent advent of HER2 ADC has shown some clinical benefits, its efficacy in real-world clinical settings remains largely uncharted. Thus, we conducted a multi-center retrospective study to assess the efficacy of HER2 ADC in a real-world context.
Methods
We continuously enrolled patients with ERBB2-altered NSCLC who underwent monotherapy or combination therapy with Disitamab Vedotin (RC48) between August 2021 and March 2023.
Results
A total of 22 patients with HER2 alterations were enrolled, including 15 with HER2 mutations, 5 with HER2 amplifications, and 2 with both. The overall objective response rate (ORR) was 45.5% (10/22), disease control rate (DCR) was 90.9% (20/22), and median progression-free survival (mPFS) stood at 7.5 months (95% CI 6.6-8.4 months). 95.5% of patients (21/22) underwent combination therapy, yielding an ORR of 47.6% (10/21). Combination regimens includes platinum, anti-angiogenesis, HER2 TKIs, and PD-1/PD-L1 inhibitors. Of note, the platinum-based combination regimen shows the highest ORR at 71.4% (5/7), following is HER2-TKI at 50% (4/8). First-line treatment patients experienced an ORR of 62.5% (5/8), whereas second-line and third-line or beyond treatments demonstrated ORRs of 57.1% (4/7) and 14.3% (1/7) respectively. No significant difference in mPFS was observed between 1L and 2L or subsequent treatments. The mPFS was notably prolonged in HER2-amplified patients and anti-HER2 naïve patients.
Conclusions
For HER2-altered NSCLC patients, RC48 combined therapies are applicable treatment options, particularly with platinum agents. RC48 combined therapies also offers a new treatment approach for patients with HER2 amplification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract